Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.49 |
| ▸ | FEN1 | P39748 | 4/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162273 | 1.00 | SCN9A (0.54) | SCN9AALOX5APFEN1CHEK2BACE1 | |
| SCHEMBL5163390 | 1.00 | SCN9A (0.54) | SCN9AALOX5APFEN1CHEK2BACE1 | |
| SCHEMBL27681575 | 0.87 | PTGDR2 (0.43) | RBP4 | |
| SCHEMBL27700745 | 0.87 | PTGDR2 (0.43) | RBP4 | |
| SCHEMBL27681576 | 0.87 | PTGDR2 (0.43) | RBP4 | |
| SCHEMBL5163789 | 0.85 | SCN9A (0.51) | SCN9AALOX5APFEN1CHEK2MAPT | |
| SCHEMBL5163780 | 0.85 | SCN9A (0.51) | SCN9AALOX5APFEN1CHEK2MAPT | |
| SCHEMBL5166008 | 0.85 | SCN9A (0.51) | SCN9AALOX5APFEN1CHEK2MAPT | |
| SCHEMBL4510756 | 0.84 | CHEK2 (0.55) | SCN9AALOX5APFEN1CHEK2MAPT | |
| SCHEMBL13122449 | 0.84 | CHEK2 (0.55) | SCN9AALOX5APFEN1CHEK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318974-A1 | Compounds Useful for Inhibiting Chk1 | ICOS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1778648-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006021002-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318974-A1 | Compounds Useful for Inhibiting Chk1 | CHEK1, PCNA, CHEK2 | SCN9A 4533/4885ALOX5AP 4143/4885FEN1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.